xNA Molecule Length Tuning for SERCA Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiac disease, particularly those targeting the SERCA/PLN complex, face challenges in achieving predictable and tunable effects on SERCA activity, stability, delivery to affected tissues, and cost-effectiveness, with existing molecules exhibiting weak affinity and lack of tunability.
Innovation Solution
The use of single-stranded xNA molecules, such as ssDNA and RNA, which bind to phospholamban (PLN) in a length-dependent manner to modulate SERCA inhibition, offering high affinity and tunable modulation of SERCA activity independent of nucleotide sequence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing molecules are used to target SERCA/PLN complex, then treatment can be administered, but affinity is weak and tunability is lacking
Solution Approach 1:
The patent applies parameter changes by systematically varying the length of xNA molecules (from 6 to 100 nucleotides) to achieve different binding affinities to phospholamban. This length-dependent binding provides a tunable parameter that allows precise control over SERCA modulation strength, directly resolving the contradiction between achieving high affinity and maintaining tunability.
Solution Approach 2:
The invention introduces dynamics through the ability to adjust xNA molecule length dynamically to match different therapeutic needs. By selecting appropriate lengths (e.g., shorter for mild modulation, longer for strong inhibition), the system adapts its affinity characteristics to achieve both high reliability and versatility across different cardiac disease scenarios.
2Reliability
If existing treatments are used, then SERCA activity can be targeted, but effects are not predictable or tunable
Solution Approach 1:
The patent establishes a direct relationship between xNA length parameter and SERCA modulation effect. By changing the length parameter, practitioners can predictably control the degree of SERCA inhibition, achieving both reliability in effect prediction and versatility in tuning the therapeutic response to match individual patient needs.
3Reliability
If longer xNA molecules are used, then affinity and modulation strength increase, but delivery efficiency and cost-effectiveness may decrease
Solution Approach 1:
The invention enables dynamic selection of xNA length based on therapeutic requirements. For cases requiring strong modulation, longer molecules are used; for situations where delivery efficiency and cost are prioritized, shorter molecules suffice. This dynamic approach optimizes the balance between modulation strength and manufacturing/delivery considerations.
Solution Approach 2:
By treating xNA length as a可调 parameter, the patent allows optimization of the trade-off between modulation strength and delivery efficiency. The ability to adjust this parameter enables selection of the most cost-effective and deliverable molecule length for each specific clinical scenario.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise tuning of SERCA activity, improving myocyte relaxation and cardiac function by reducing the time required to return to baseline after contraction, without affecting contractility, and is calcium-independent, addressing the limitations of existing therapies.
Implementation Method 1
single-stranded xNA molecules, such as ssDNA and RNA, which bind to phospholamban (PLN) in a length-dependent manner to modulate SERCA inhibition
Data Source
AI summary
This disclosure describes, in one aspect, a composition that generally includes an xNA molecule comprising at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating cardiac disease. Generally, the method includes administering to a subject a composition that includes an xNA molecule having at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function, and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method for evaluating the efficacy of treatment of cardiac disease. Generally, the method includes administering to a subject a composition that includes a first xNA molecule comprising a predetermined length in an amount effective to increase myocyte relaxation, then selecting a predetermined length of a second xNA molecule for at least one subsequent treatment. If treatment with the first xNA results in more myocyte relaxation than is desired, then the predetermined length of the second xNA molecule is shorter than the predetermined length of the first xNA. If, on the other hand, treatment with the first xNA results in less myocyte relaxation than is desired then the predetermined length of the second xNA molecule is longer than the predetermined length of the first xNA.